9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers

Cancer Letters

Volumn 201, Issue 1, 2003, Pages 17-24

  Grubbs, Clinton J ^a,d   Hill, Donald L ^a   Bland, Kirby I ^a   Beenken, Samuel W ^a   Lin, Tsu Han ^c   Eto, Isao ^b   Atigadda, Venkatram R ^b   Vines, Kimberly K ^b   Brouillette, Wayne J ^b   Muccio, Donald D ^b  

^a Kentucky   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d Volker Hall G78 B   (United States)

Author keywords

Chemoprevention; Mammary cancer; Methylnitrosourea; Retinoid; Tamoxifen

Indexed keywords

METHYLNITROSOUREA; RETINOID DERIVATIVE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEEDING; FEMALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT;

EID: 0142122347     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00461-0     Document Type: Article

References (30)

1. Evans T.R.J., Kaye S.B. Retinoids: present role and future potential. Br. J. Cancer. 80:1998;1-8.
2. Verma A.K., Garcia C.T., Ashendel C.L., Boutwell R.K. Inhibition of 7-bromomethylbenz [a]anthracene-promoted mouse skin tumor formation by retinoic acid and dexamethasone. Cancer Res. 43:1983;3045-3059.
3. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Clinical Results. Blood. 76:1990;1704-1709.
4. Delia D., Aiello A., Formelli F., Fontanella E., Costa A., Miyashita T., Reed J.C., Pierotti M.A. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood. 85:1995;359-367.
5. Eppinger T.M., Buck J., Hammerling U. Growth control or terminal differentiation: endogenous production and differential activities of vitamin A metabolites in HL-60 cells. J. Exp. Med. 178:1993;1995-2005.
6. Sani B.P., Singh R.K., Reddy L.G., Gaub M.P. Isolation, partial purification and characterization of nuclear retinoic acid receptors from chick skin. Arch. Biochem. Biophys. 283:1990;107-113.
7. Zhang X.-K., Pfahl M. Regulation of retinoid and thyroid hormone action through homodimeric and heterodimeric receptors. Trends Endocrinol. Metab. 4:1993;156-162.
8. Kim Y.W., Sharma R.P., Li J.K.K. Characterization of heterologously expressed recombinant retinoic acid receptors with natural or synthetic retinoids. J. Biochem. Toxicol. 9:1994;225-234.
9. Mangelsdorf D.J., Umesons K., Evans R.M. The retinoids receptors. Sporn M.B., Roberts A.B., Goodman D.S. second ed The Retinoids Biology, Chemistry and Medicine. 1994:1994;319-349 Raven Press, New York.
10. Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele G., Evans R.M., Thaller C. 9-cis-Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 68:1992;397-406.
11. Zhang X.-K., Lehmann J.M., Hoffmann B., Dawson M.I., Cameron J., Graupner G., Hermann T., Tran O., Pfahl M. Homodimer formation of retinoids X receptor induced by 9-cis retinoic acid. Nature (London). 358:1992;587-591.
12. Anzano M.A., Byers W.W., Smith J.M., Peer C.W., Mullen L.T., Brown C.C., Roberts A.B., Sporn M.B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:1994;4614-4617.
13. Miller V.A., Rigas J.R., Benedetti F.M., Verret A.L., Tong W.P., Kris M.G., Gill G.M., Loewen G.R., Truglia J.A., Ulm E.H., Warrell R.P. Jr. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin. Cancer Res. 2:1996;471-475.
14. Lee J.S., Newman R.A., Lippman S.M., Huber M.H., Minor T., Raber M.N., Krakoff I.H., Hong W.K. Phase 1 evaluation of all-trans-retinoic acid in adults with solid tumors. J. Clin. Oncol. 11:1993;959-966.
15. Jonathan J.K., Lotan R., Lee J.J., Lee J.S., Morice R.C., Liu D.D., Xu X.-C., Khuri F.R., Ro J.Y., Hittelman W.H., Walsh G.L., Roth J.A., Minna J.D., Hong W.K. Treatment of former smokers with 9-cis-retinoic acid reverse loss of retinoic acid receptor-β expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl Cancer Inst. 95:2003;206-214.
16. Lehmann J.M., Jong L., Fanjul A., Cameron J.F., Lu X.P., Haefner P., Dawson M.A., Pfahl M. Retinoids selective for retinoid x receptor response pathways. Science. 1992;1944-1946.
17. Boehm M.F., Zhang L., Badea B.A., White S.K., Mais D.E., Berger E., Suto C.M., Goldman M.E., Heyman R.A. Synthesis and structure-activity relationships of novel X receptor-selective retinoids. J. Med. Chem. 37:1994;2930-2941.
18. Vaezi M.F., Alam M., Sani B.P., Rogers T.S., Simpson-Herren L., Wille J.J., Hill D.L., Doran T.I., Brouillette W.J., Muccio D.D. A conformationally defined 6-s-trans retinoic acid isomer: synthesis, chemopreventive activity and toxicity. J. Med. Chem. 37:1994;4499-4507.
19. Muccio D.D., Brouillette W.J., Breitman T.R., Taimi M., Emanuel P.D., Zhang X., Chen G., Sani B.P., Venepally P., Reddy L., Alam M., Simpson-Herren L., Hill D.L. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J. Med. Chem. 41:1998;1679-1687.
20. Suh N., Glasebrook A.L., Palkowitz A.D., Bryant H.V., Burris L.L., Starling J.J., Pearce H.L., Williams C., Peer C., Wang Y., Sporn M.B. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61:2001;8412-8415.
21. Fried K.M., Wainer I.W. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B655:1994;261-268.
22. Peto J. The calculation and interpretation of survival cancers. Buyse M.E., Staquet M.J., Sylvester R.J. Cancer Clinical Trials: Methods and Practice. 1984;361-380 Oxford University Press, Oxford.
23. Armitage P. The Chi-square test for heterogeneity of proportion after adjustment for stratification. J. R. Statist. Soc. B. 28:1966;150-153.
24. Gottardis M.M., Bischoff E.D., Shirley M.A., Wagoner M.A., Lamph W.W., Heyman R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin). Cancer Res. 56:1996;5566-5570.
25. Grubbs C.J., Steele V.E., Eto I., Cope M.B., Lubet R.A. Dose levels of tamoxifen (TAM) and 9-cis-retinoic acid (9cRA), alone or in combination, required to achieve chemopreventive and chemotherapeutic activity. Proc. Am. Assoc. Cancer Res. 42:2001;309.
26. Lubet R.A., Steele V.E., Kelloff G.J., Eto I., Grubbs C.J. Chemopreventive efficacy of 9-cis retinoic acid (9cRA) administered singly or concurrently with toremifene or vorozole in the MNU-induced rat mammary tumor model. Proc. Am. Assoc. Cancer Res. 39:1998;197.
27. Bischoff E.D., Gottardis M.M., Moon T.E., Heyman R.A., Lamph W.W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res. 58:1998;479-484.
28. Duvic M., Martin A.G., Kim Y., Olsen E., Wood G.S., Crowley C.A., Yocum R.C. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 137:2001;581-593.
29. Ratko T.A., Detrisac C.J., Dinger N.M., Thomas C.F., Kelloff G.J., Moon R.C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49:1989;4472-4476.
30. Wu K., Zhang Y., Xu C., Hill J., Celestino J., Kim H.T., Mohsin S.K., Hilsenbeck S.G., Lamph W.W., Bissonette R., Brown P.H. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 62:2002;6376-6380.